CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: benzothiadiazine
Accession: CHEBI:50265
browse the term
Definition: Heterocyclic compound of a ring with sulfur and two nitrogen atoms fused to a benzene ring. Members inhibit sodium-potassium-chloride symporters and are used as diuretics.
Synonyms: related_synonym: Benzothiadiazines
G
Apob
apolipoprotein B
affects expression
ISO
Bendroflumethiazide affects the expression of APOB protein
CTD
PMID:2344503
NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
G
Ren
renin
increases expression
ISO
Bendroflumethiazide results in increased expression of REN protein
CTD
PMID:62162
NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
G
Slc12a3
solute carrier family 12 member 3
increases response to substance
EXP
SLC12A3 protein results in increased susceptibility to Bendroflumethiazide
CTD
PMID:18480177
NCBI chr19:11,106,033...11,144,674
Ensembl chr19:11,106,033...11,144,641
G
Slc22a6
solute carrier family 22 member 6
decreases activity increases secretion
ISO
Bendroflumethiazide results in decreased activity of SLC22A6 protein SLC22A6 protein results in increased secretion of Bendroflumethiazide
CTD
PMID:18216144
NCBI chr 1:224,824,809...224,833,284
Ensembl chr 1:224,824,799...224,833,259
G
Slc22a8
solute carrier family 22 member 8
decreases activity increases secretion
ISO
Bendroflumethiazide results in decreased activity of SLC22A8 protein SLC22A8 protein results in increased secretion of Bendroflumethiazide
CTD
PMID:18216144
NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
G
Tpmt
thiopurine S-methyltransferase
decreases activity
ISO
Bendroflumethiazide results in decreased activity of TPMT protein
CTD
PMID:8866635
NCBI chr17:18,029,090...18,047,716
Ensembl chr17:18,029,124...18,047,714
G
Vegfc
vascular endothelial growth factor C
decreases expression
EXP
Bendroflumethiazide results in decreased expression of VEGFC protein
CTD
PMID:20625077
NCBI chr16:40,440,371...40,555,178
Ensembl chr16:40,440,207...40,555,576
G
Alb
albumin
increases secretion multiple interactions
EXP
bentazone results in increased secretion of ALB protein [bentazone co-treated with Dicamba] results in increased secretion of ALB protein
CTD
PMID:25863332
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
G
Sfrp4
secreted frizzled-related protein 4
affects binding
ISO
cyclothiazide binds to SFRP4 protein
CTD
PMID:25019556
NCBI chr17:47,383,983...47,394,065
Ensembl chr17:47,297,489...47,394,328
G
Aifm1
apoptosis inducing factor, mitochondria associated 1
decreases localization multiple interactions
EXP
Diazoxide results in decreased localization of AIFM1 protein 5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in decreased localization of AIFM1 protein]
CTD
PMID:21256120
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
G
Akt1
AKT serine/threonine kinase 1
multiple interactions increases phosphorylation
EXP
5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in increased phosphorylation of AKT1 protein]
CTD
PMID:21256120
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
G
Bax
BCL2 associated X, apoptosis regulator
multiple interactions
EXP
Diazoxide inhibits the reaction [Streptozocin results in increased expression of BAX protein]
CTD
PMID:20650802
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
G
Bcl2
BCL2, apoptosis regulator
multiple interactions
EXP
Diazoxide inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein]
CTD
PMID:20650802
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
G
Bcl2l1
Bcl2-like 1
multiple interactions increases expression
ISO
5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in increased expression of BCL2L1 mRNA alternative form]; 5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in increased expression of BCL2L1 protein alternative form] Diazoxide results in increased expression of BCL2L1 mRNA alternative form; Diazoxide results in increased expression of BCL2L1 protein alternative form
CTD
PMID:15326191
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
G
Casp3
caspase 3
multiple interactions decreases activity
EXP
5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in decreased activity of CASP3 protein]
CTD
PMID:21256120
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
G
Ccnd1
cyclin D1
multiple interactions decreases expression
ISO
Diazoxide inhibits the reaction [CTNNB1 protein results in increased activity of CCND1 promoter] Diazoxide results in decreased expression of CCND1 mRNA
CTD
PMID:19052819
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
G
Ctnnb1
catenin beta 1
multiple interactions decreases expression
ISO
Diazoxide inhibits the reaction [CTNNB1 protein results in increased activity of CCND1 promoter] Diazoxide results in decreased expression of CTNNB1 protein
CTD
PMID:19052819
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
G
Cycs
cytochrome c, somatic
decreases secretion multiple interactions
EXP
Diazoxide results in decreased secretion of CYCS protein 5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in decreased secretion of CYCS protein]
CTD
PMID:21256120
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
G
Flt1
Fms related receptor tyrosine kinase 1
multiple interactions
ISO
5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]]; Diazoxide inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]; HMOX1 protein affects the reaction [Diazoxide inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]]; zinc protoporphyrin inhibits the reaction [Diazoxide inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]]
CTD
PMID:25371888
NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
G
Gcg
glucagon
multiple interactions
ISO
Diazoxide inhibits the reaction [gatifloxacin results in increased secretion of GCG protein]
CTD
PMID:23200776
NCBI chr 3:48,442,635...48,451,650
Ensembl chr 3:48,442,635...48,451,650
G
Gpd2
glycerol-3-phosphate dehydrogenase 2
multiple interactions
ISO
[Potassium Chloride co-treated with Diazoxide] inhibits the reaction [[GPD2 mutant form co-treated with Aminooxyacetic Acid] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]
CTD
PMID:10464266
NCBI chr 3:43,223,892...43,359,069
Ensembl chr 3:43,255,567...43,359,074
G
Hmox1
heme oxygenase 1
multiple interactions
ISO
Diazoxide inhibits the reaction [Oxygen deficiency results in decreased expression of HMOX1 mRNA]; Diazoxide inhibits the reaction [Oxygen deficiency results in decreased expression of HMOX1 protein]; HMOX1 protein affects the reaction [Diazoxide inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]]
CTD
PMID:25371888
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
G
Iapp
islet amyloid polypeptide
multiple interactions
EXP
Diazoxide inhibits the reaction [Glucose results in increased expression of IAPP mRNA]
CTD
PMID:9142872
NCBI chr 4:176,509,863...176,517,903
Ensembl chr 4:176,510,696...176,516,083
G
Il10
interleukin 10
decreases secretion
ISO
Diazoxide results in decreased secretion of IL10 protein
CTD
PMID:16612254
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
G
Il6
interleukin 6
decreases secretion
ISO
Diazoxide results in decreased secretion of IL6 protein
CTD
PMID:16612254
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
G
Kcnj11
potassium inwardly-rectifying channel, subfamily J, member 11
decreases expression
ISO
Diazoxide results in decreased expression of KCNJ11 mRNA
CTD
PMID:23200776
NCBI chr 1:102,103,093...102,107,134
Ensembl chr 1:102,103,094...102,106,127
G
Lep
leptin
multiple interactions decreases secretion
EXP
Diazoxide inhibits the reaction [[Glucose co-treated with INS1 protein] results in increased secretion of LEP protein] Diazoxide results in decreased secretion of LEP protein
CTD
PMID:10780946
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
G
Nampt
nicotinamide phosphoribosyltransferase
multiple interactions
ISO
Diazoxide inhibits the reaction [Glucose results in increased secretion of NAMPT protein]
CTD
PMID:23536823
NCBI chr 6:52,122,085...52,156,473
Ensembl chr 6:52,122,085...52,156,472
G
Nfkb1
nuclear factor kappa B subunit 1
multiple interactions increases activity
ISO
5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in increased activity of NFKB1 protein]
CTD
PMID:15326191
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
G
Nos2
nitric oxide synthase 2
multiple interactions
ISO EXP
5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Rotenone results in increased expression of and results in increased activity of NOS2 protein]]; Diazoxide inhibits the reaction [Rotenone results in increased expression of and results in increased activity of NOS2 protein] 5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Rotenone results in increased activity of NOS2 protein]]; 5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Rotenone results in increased expression of NOS2 mRNA]]; Diazoxide inhibits the reaction [Rotenone results in increased activity of NOS2 protein]; Diazoxide inhibits the reaction [Rotenone results in increased expression of NOS2 mRNA]
CTD
PMID:15795934 PMID:15927086 PMID:16257489
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
G
Pdx1
pancreatic and duodenal homeobox 1
multiple interactions
EXP
Diazoxide inhibits the reaction [Bezafibrate results in decreased expression of PDX1 mRNA]
CTD
PMID:11527545
NCBI chr12:9,496,044...9,501,211
Ensembl chr12:9,496,044...9,501,213
G
Slc2a2
solute carrier family 2 member 2
multiple interactions
EXP
Diazoxide inhibits the reaction [Bezafibrate results in decreased expression of SLC2A2 mRNA]
CTD
PMID:11527545
NCBI chr 2:114,413,427...114,445,418
Ensembl chr 2:114,413,410...114,445,395
G
Tnf
tumor necrosis factor
decreases secretion multiple interactions
ISO EXP
Diazoxide results in decreased secretion of TNF protein 5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of TNF protein]]; 5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Rotenone results in increased expression of TNF protein]]; Diazoxide inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of TNF protein]; Diazoxide inhibits the reaction [Rotenone results in increased expression of TNF protein] 5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Rotenone results in increased secretion of TNF protein]]; Diazoxide inhibits the reaction [Rotenone results in increased secretion of TNF protein]
CTD
PMID:16257489 PMID:16612254 PMID:18700057 PMID:19012619
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
G
Tp53
tumor protein p53
decreases expression
EXP
Diazoxide results in decreased expression of TP53 mRNA
CTD
PMID:16426753
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
G
Abcc4
ATP binding cassette subfamily C member 4
increases transport increases export
ISO
ABCC4 protein results in increased transport of Hydrochlorothiazide ABCC4 protein results in increased export of Hydrochlorothiazide
CTD
PMID:17135398 PMID:17939016
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
G
Ace
angiotensin I converting enzyme
increases expression multiple interactions
EXP
Hydrochlorothiazide results in increased expression of ACE mRNA Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACE mRNA]
CTD
PMID:16326922 PMID:18796534
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
G
Acta1
actin, alpha 1, skeletal muscle
multiple interactions
EXP
Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACTA1 mRNA]
CTD
PMID:16326922
NCBI chr19:56,674,072...56,677,084
Ensembl chr19:56,674,074...56,677,084
G
Adipoq
adiponectin, C1Q and collagen domain containing
decreases expression
ISO
Hydrochlorothiazide results in decreased expression of ADIPOQ mRNA
CTD
PMID:19730415
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
G
Agtr1a
angiotensin II receptor, type 1a
decreases expression
EXP
Hydrochlorothiazide results in decreased expression of AGTR1A mRNA
CTD
PMID:18796534
NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
G
Aqp2
aquaporin 2
decreases expression multiple interactions
EXP
Hydrochlorothiazide results in decreased expression of AQP2 mRNA; Hydrochlorothiazide results in decreased expression of AQP2 protein Hydrochlorothiazide inhibits the reaction [Lithium results in decreased expression of AQP2 protein]
CTD
PMID:15504936 PMID:17584643
NCBI chr 7:141,237,802...141,242,837
Ensembl chr 7:141,237,768...141,245,165
G
Atp6v1b1
ATPase H+ transporting V1 subunit B1
increases expression
EXP
Hydrochlorothiazide results in increased expression of ATP6V1B1 protein
CTD
PMID:17311909
NCBI chr 4:115,417,100...115,435,754
Ensembl chr 4:115,416,580...115,437,206
G
Avp
arginine vasopressin
affects secretion
ISO
Hydrochlorothiazide affects the secretion of AVP protein
CTD
PMID:6635723
NCBI chr 3:123,117,482...123,119,460
Ensembl chr 3:123,117,492...123,119,460
G
Avpr2
arginine vasopressin receptor 2
decreases expression
EXP
Hydrochlorothiazide results in decreased expression of AVPR2 mRNA
CTD
PMID:17584643
NCBI chr X:156,889,006...156,892,707
Ensembl chr X:156,889,410...156,891,213
G
Bdkrb1
bradykinin receptor B1
decreases expression
EXP
Hydrochlorothiazide results in decreased expression of BDKRB1 mRNA
CTD
PMID:18796534
NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574
G
Cat
catalase
multiple interactions decreases activity
EXP
[Hydrochlorothiazide co-treated with Fructose] results in decreased activity of CAT protein Hydrochlorothiazide results in decreased activity of CAT protein
CTD
PMID:23707192
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
G
Ccl2
C-C motif chemokine ligand 2
decreases expression
EXP
Hydrochlorothiazide results in decreased expression of CCL2 mRNA
CTD
PMID:19627010
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
G
Cdkn1b
cyclin-dependent kinase inhibitor 1B
multiple interactions
EXP
[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of CDKN1B protein
CTD
PMID:11318962
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
G
Cdkn2a
cyclin-dependent kinase inhibitor 2A
multiple interactions
EXP
[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate affects the localization of CDKN2A protein]; [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate results in increased expression of CDKN2A mRNA]
CTD
PMID:18504326
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
G
Cma1
chymase 1
affects expression
EXP
Hydrochlorothiazide affects the expression of CMA1 mRNA
CTD
PMID:18796534
NCBI chr15:34,601,037...34,603,819
Ensembl chr15:34,601,037...34,603,819
G
Cyba
cytochrome b-245 alpha chain
multiple interactions
EXP
Hydrochlorothiazide promotes the reaction [candesartan results in decreased expression of CYBA]
CTD
PMID:21107329
NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
G
Cybb
cytochrome b-245 beta chain
multiple interactions
EXP
Hydrochlorothiazide promotes the reaction [candesartan results in decreased expression of CYBB]
CTD
PMID:21107329
NCBI chr X:14,578,330...14,610,049
Ensembl chr X:14,578,264...14,612,547
G
Cyp11b3
cytochrome P450, family 11, subfamily b, polypeptide 3
increases expression
EXP
Hydrochlorothiazide results in increased expression of CYP11B2 mRNA
CTD
PMID:18796534
NCBI chr 7:116,155,928...116,161,781
Ensembl chr 7:116,156,219...116,255,167
G
Edn1
endothelin 1
multiple interactions
EXP
Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of EDN1 mRNA]
CTD
PMID:16326922
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
G
Flt1
Fms related receptor tyrosine kinase 1
multiple interactions
EXP
[Hydralazine co-treated with Hydrochlorothiazide] inhibits the reaction [Cyclosporine results in increased expression of FLT1 mRNA]
CTD
PMID:12110003
NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
G
Klk1
kallikrein 1
increases expression
EXP
Hydrochlorothiazide results in increased expression of KLK1 mRNA
CTD
PMID:18796534
NCBI chr 1:100,131,562...100,135,556
Ensembl chr 1:100,059,967...100,203,329 Ensembl chr 1:100,059,967...100,203,329 Ensembl chr 1:100,059,967...100,203,329
G
Lepr
leptin receptor
increases response to substance
ISO
LEPR mutant form results in increased susceptibility to Hydrochlorothiazide
CTD
PMID:22949526
NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
G
Mr1
major histocompatibility complex, class I-related
affects expression
ISO
Hydrochlorothiazide affects the expression of MR1 mRNA
CTD
PMID:25811541
NCBI chr13:72,771,992...72,789,861
Ensembl chr13:72,771,984...72,789,841
G
Myh7
myosin heavy chain 7
multiple interactions
EXP
Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of MYH7 mRNA]
CTD
PMID:16326922
NCBI chr15:33,605,769...33,657,761
Ensembl chr15:33,634,422...33,656,089
G
Nos3
nitric oxide synthase 3
multiple interactions
EXP
Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in decreased expression of NOS3 protein]
CTD
PMID:16197366
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
G
Nox1
NADPH oxidase 1
multiple interactions
EXP
Hydrochlorothiazide promotes the reaction [candesartan results in decreased expression of NOX1]
CTD
PMID:21107329
NCBI chr X:104,909,328...104,932,508
Ensembl chr X:104,909,326...104,932,508
G
Nox4
NADPH oxidase 4
multiple interactions
EXP
Hydrochlorothiazide promotes the reaction [candesartan results in decreased expression of NOX4]
CTD
PMID:21107329
NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
G
Nppb
natriuretic peptide B
multiple interactions
EXP
Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPB mRNA]
CTD
PMID:16326922
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
G
Nr3c2
nuclear receptor subfamily 3, group C, member 2
increases expression
EXP
Hydrochlorothiazide results in increased expression of NR3C2 mRNA
CTD
PMID:18796534
NCBI chr19:34,408,275...34,761,003
Ensembl chr19:34,448,289...34,752,695
G
Pcna
proliferating cell nuclear antigen
multiple interactions
EXP
[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of PCNA protein
CTD
PMID:11318962
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
G
Ptgs2
prostaglandin-endoperoxide synthase 2
multiple interactions
EXP
[rofecoxib results in decreased activity of PTGS2 protein] inhibits the reaction [Hydrochlorothiazide results in increased abundance of Prostaglandins]
CTD
PMID:11703585
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
G
Ramp2
receptor activity modifying protein 2
multiple interactions
EXP
Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP2 protein]
CTD
PMID:16326922
NCBI chr10:89,166,170...89,168,962
Ensembl chr10:89,166,890...89,168,965
G
Ramp3
receptor activity modifying protein 3
multiple interactions
EXP
Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP3 protein]
CTD
PMID:16326922
NCBI chr14:86,922,223...86,939,722
Ensembl chr14:86,922,223...86,939,719
G
Ren
renin
increases activity multiple interactions increases expression
ISO EXP
Hydrochlorothiazide results in increased activity of REN protein Losartan promotes the reaction [Hydrochlorothiazide results in increased expression of REN protein]; Sodium affects the reaction [Hydrochlorothiazide results in increased activity of REN protein]
CTD
PMID:1930859 PMID:2920503 PMID:11135058 PMID:12569265
NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
G
RT1-CE5
RT1 class I, locus CE5
affects expression
ISO
Hydrochlorothiazide affects the expression of HLA-F mRNA
CTD
PMID:25811541
NCBI chr20:4,892,702...4,896,993
Ensembl chr20:4,892,702...4,896,991
G
RT1-Db1
RT1 class II, locus Db1
affects expression
ISO
Hydrochlorothiazide affects the expression of HLA-DRB1 mRNA
CTD
PMID:25811541
NCBI chr20:4,087,621...4,097,190
Ensembl chr20:4,087,618...4,097,190
G
RT1-Ha
RT1 class II, locus Ha
affects expression
ISO
Hydrochlorothiazide affects the expression of HLA-DPA1 mRNA
CTD
PMID:25811541
NCBI chr20:3,875,478...3,885,140
Ensembl chr20:3,875,706...3,881,461
G
RT1-S3
RT1 class Ib, locus S3
affects expression
ISO
Hydrochlorothiazide affects the expression of HLA-E mRNA
CTD
PMID:25811541
NCBI chr20:3,176,124...3,180,825
Ensembl chr20:3,176,107...3,179,818
G
Serpine1
serpin family E member 1
multiple interactions
EXP
[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of SERPINE1 mRNA; [troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of SERPINE1 protein
CTD
PMID:11318962
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
G
Slc22a6
solute carrier family 22 member 6
increases expression
EXP
Hydrochlorothiazide results in increased expression of SLC22A6 protein
CTD
PMID:12897087
NCBI chr 1:224,824,809...224,833,284
Ensembl chr 1:224,824,799...224,833,259
G
Slc12a7
solute carrier family 12 member 7
decreases activity
ISO
Trichlormethiazide results in decreased activity of SLC12A7 protein
CTD
PMID:10913127
NCBI chr 1:32,086,755...32,167,950
Ensembl chr 1:32,086,755...32,141,036
G
Slc47a1
solute carrier family 47 member 1
multiple interactions
ISO
Trichlormethiazide inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]
CTD
PMID:22419765
NCBI chr10:47,631,425...47,685,379
Ensembl chr10:47,632,192...47,666,921
G
Slc47a2
solute carrier family 47 member 2
multiple interactions
ISO
Trichlormethiazide affects the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]
CTD
PMID:22419765
NCBI chr10:47,587,909...47,631,373
Ensembl chr10:47,588,497...47,630,799
G
Tpmt
thiopurine S-methyltransferase
decreases activity
ISO
Trichlormethiazide results in decreased activity of TPMT protein
CTD
PMID:8866635
NCBI chr17:18,029,090...18,047,716
Ensembl chr17:18,029,124...18,047,714
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all
Path 1
CHEBI ontology
19853
chemical entity
19853
atom
19851
nonmetal atom
19733
nitrogen atom
18620
nitrogen molecular entity
18620
organonitrogen compound
18395
organonitrogen heterocyclic compound
17564
thiazide
74
benzothiadiazine
74
3-fluoro-6a,7,8,9,10,11-hexahydro-6H-azepino[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide
0
6-chloro-1,1-dioxo-3-[(prop-2-enylthio)methyl]-3,4-dihydro-2H-1$l^\{6\},2,4-benzothiadiazine-7-sulfonamide
0
6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^\{6\},2,4-benzothiadiazine-7-sulfonamide
0
7-chloro-3-methyl-3,4-dihydro-2H-1$l^\{6\},2,4-benzothiadiazine 1,1-dioxide
0
Benzylhydrochlorothiazide
0
Ethiazide
0
Methyclothiazide
0
Polythiazide
0
bemetizide
0
bendroflumethiazide +
7
bentazone
1
benzthiazide
0
butizide
0
chlorothiazide
0
cyclothiazide
1
diazoxide
25
epitizide
0
flumethiazide
0
hydrochlorothiazide
40
hydroflumethiazide
0
mebutizide
0
teclothiazide
0
trichlormethiazide
4
Path 2
CHEBI ontology
19853
subatomic particle
19851
composite particle
19851
hadron
19851
baryon
19851
nucleon
19851
atomic nucleus
19851
atom
19851
main group element atom
19744
main group molecular entity
19744
p-block molecular entity
19744
carbon group molecular entity
19650
organic molecular entity
19639
organic molecule
19568
organic cyclic compound
19378
organic heterocyclic compound
18495
organonitrogen heterocyclic compound
17564
thiazide
74
benzothiadiazine
74
3-fluoro-6a,7,8,9,10,11-hexahydro-6H-azepino[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide
0
6-chloro-1,1-dioxo-3-[(prop-2-enylthio)methyl]-3,4-dihydro-2H-1$l^\{6\},2,4-benzothiadiazine-7-sulfonamide
0
6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^\{6\},2,4-benzothiadiazine-7-sulfonamide
0
7-chloro-3-methyl-3,4-dihydro-2H-1$l^\{6\},2,4-benzothiadiazine 1,1-dioxide
0
Benzylhydrochlorothiazide
0
Ethiazide
0
Methyclothiazide
0
Polythiazide
0
bemetizide
0
bendroflumethiazide +
7
bentazone
1
benzthiazide
0
butizide
0
chlorothiazide
0
cyclothiazide
1
diazoxide
25
epitizide
0
flumethiazide
0
hydrochlorothiazide
40
hydroflumethiazide
0
mebutizide
0
teclothiazide
0
trichlormethiazide
4